ABL Diagnostics
ISIN: FR001400AHX6 | Ticker: ABLD | LEI: 9695002UO0UHM0VKRH38
Country: France
Advanced Biological Laboratories (ABL), S.A., is a diagnostic and medical software company founded in 2000 as a spin-off from CRP-Santé (https://www.lih.lu/) Luxembourg.
ABL’s products offer to infectious disease clinicians, virology and microbiology laboratories.
Assays and standalone software systems for accredited laboratories (i.e. ISO 15189), mainly for microbiology applications (related to HIV, SARS-CoV-2, Tuberculosis, HCV, HBV, HPV, CMV, HPV, Flu, 16s RNA…) for clinical genotyping through sequencing (DeepChek®), DNA and RNA detection and quantification (UltraGene®), including powerful downstream analysis software applications fully integrated with knowledge databases and analysis systems for capillary and high-throughput Next Generation Sequencing data.
Clinical software applications for infectious diseases units
IT dashboards and clinical database aggregation applications for research and clinical management
2000
Served areaWorldwide
HeadquartersBât E1 42 Rue Olivier Métra, 75020 Paris – France
FR001400AHX6
LEI9695002UO0UHM0VKRH38
SectorHealth Care Equipment & Services
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.